Antacid Therapy and Disease Progression in Patients with Idiopathic Pulmonary Fibrosis Who Received Pirfenidone

BACKGROUND: Gastroesophageal reflux disease is a potential risk factor for idiopathic pulmonary fibrosis (IPF) progression; however, the impact of antacid therapy (AAT) is under debate. OBJECTIVE: To evaluate the effect of AAT on IPF progression in pirfenidone-treated patients. METHODS: This post ho...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Respiration
Main Authors: Kreuter, Michael, Spagnolo, Paolo, Wuyts, Wim, Renzoni, Elisabetta, Koschel, Dirk, Bonella, Francesco, Maher, Toby M., Kolb, Martin, Weycker, Derek, Kirchgässler, Klaus-Uwe, Costabel, Ulrich
Formato: Artigo
Idioma:Inglês
Publicado: S. Karger AG 2017
Assuntos:
Clinical Investigations
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5452370/
https://ncbi.nlm.nih.gov/pubmed/28399537
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000468546
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares